Keros Therapeutics, Inc. 8-K

What Happened
Keros Therapeutics, Inc. filed a Form 8‑K on March 9, 2026 announcing it entered into an agreement with Massachusetts General Hospital to design a Phase 2 clinical trial evaluating rinvatercept in patients with amyotrophic lateral sclerosis (ALS). The planned trial design will be conducted within the HEALEY ALS MyMatch program led by the Sean M. Healey & AMG Center for ALS at Mass General Brigham. On the same date, Keros also issued a press release reporting additional Phase 1 clinical data for rinvatercept presented at the 2026 Muscular Dystrophy Association Clinical & Scientific Conference.

Key Details

• Date filed: March 9, 2026 (Form 8‑K).
• Clinical candidate: rinvatercept; next step is Phase 2 trial design with Massachusetts General Hospital.
• Program/partner: HEALEY ALS MyMatch program, Sean M. Healey & AMG Center for ALS at Mass General Brigham.
• Additional update: Company presented extra Phase 1 healthy-volunteer data at the 2026 MDA Clinical & Scientific Conference.
• Press releases announcing both items were attached to the 8‑K as exhibits.

Why It Matters
This filing signals development progress for Keros’s lead program: moving from Phase 1 data reporting to active planning for a Phase 2 ALS trial with a leading clinical center can be an important operational and clinical milestone. The partnership with Mass General/Healey program may help with trial design, access to ALS expertise and potential patient-matching resources. Investors should view this as a clinical development update and a potential near‑term catalyst, noting the 8‑K does not include financial results or efficacy claims.